Cutia Therapeutics (CUTIA-B) filed its Monthly Return for the period ended 30 September 2026, indicating no changes to its authorised, issued or treasury share balances and confirming continued compliance with Hong Kong’s minimum 25% public-float requirement.

Authorised and Issued Capital • Authorised share capital held steady at 2.50 billion ordinary shares with a par value of USD 0.00002 each, equal to USD 50,000. • Issued shares (excluding treasury) remained unchanged at 373.17 million, alongside 1.36 million treasury shares, bringing total issued shares to 374.53 million.

Equity Incentive Plans • Pre-IPO Share Option Program: outstanding options slipped marginally to 18.90 million after 7,100 options (0.01 million) were forfeited during the month. Potential issuance under this program stands at 18.49 million shares, with an overall programme limit of 18.58 million shares. • Post-IPO Equity Incentive Plan: no options were outstanding or exercised; the scheme retains an available pool of 30.40 million shares. • Pre-IPO Share Award Program: outstanding share awards fell to 6.06 million following the forfeiture of 0.24 million awards. Up to 2.60 million shares may still be issued under this component.

Capital Movements and Fund-raising No new shares were issued, no treasury shares were transferred, and no funds were raised in September. The company reported no warrants, convertible securities or other share-linked instruments outstanding or exercised.

Regulatory Compliance Cutia confirmed that all listing rule obligations were met, including receipt of all monies due, fulfilment of listing conditions and maintenance of identical rights across all share classes.